Arpin, D., Gautier, J., Mansuet-Lupo, A., Corre, R., Monfort, A. D., Chabaud, S., Ho, C. D. P. V., Couraud, S., Wislez, M., Yannick, S., Chaleat, S., Ricordel, C., Toffart, A. C., Debieuvre, D., Sondarjee, I., Auliac, J., Damotte, D., Greillier, L., Pérol, D., Odier, L. (2025). FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8657